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Brand names of Portuguese medication: understanding 
the importance of their linguistic structure and regulatory issues
Nomes de marca dos medicamentos Portugueses: 
sua estrutura linguística e aspetos regulatórios
Resumo  Entre outros requisitos regulatórios, o 
nome dos medicamentos de marca deve ser com-
posto por um único nome e não integrar abrevia-
turas para evitar erros de medicação. Os objetivos 
do estudo foram: investigar a adequação de um 
grupo de nomes de medicamentos de marca por-
tugueses à regulação farmacêutica do mesmo País; 
identificar as suas características linguísticas bási-
cas e comparar essas características e a sua frequ-
ência com valores de referência da língua corrente 
ou informal. Foi selecionada uma amostra de 474 
nomes. Os nomes foram analisados com recurso 
a métodos manuais (análise visual) e automá-
ticos (FreP - Frequency Patterns of Phonological 
Objects in Portuguese e o MS word). Um núme-
ro significativo de nomes (61,3%) não estava em 
conformidade com o sistema fonológico (relacio-
nado com a forma sonora das palavras) e orto-
gráfico do Português (relacionado com a forma de 
escrita das palavras), tinha mais de uma palavra, 
continha uma alta proporção padrões silábicos e 
acentuais raros, e incluía abreviaturas. Os resul-
tados sugerem que alguns dos nomes das marcas 
medicamentos portugueses devem ser reavaliadas 
e os aspetos regulatórios atualizados, tendo em 
consideração as características específicas do siste-
ma linguístico e ortográfico português.
Palavras-chave  Denominação comercial do me-
dicamento, Análise qualitativa, Linguagem, Lin-
guística, Legislação de medicamentos
Abstract  Among other regulatory requirements, 
medicine brands should be composed of single 
names without abbreviations to prevent errors in 
prescription of medication. The purposes of the 
study were to investigate the compliance of a sam-
ple of Portuguese medicine brand names with Por-
tuguese pharmaceutical regulations. This includes 
identifying their basic linguistic characteristics 
and comparing these features and their frequency 
of occurrence with benchmark values of the collo-
quial or informal language. A sample of 474 brand 
names was selected. Names were analyzed using 
manual (visual analyses) and computer methods 
(FreP - Frequency Patterns of Phonological Ob-
jects in Portuguese and MS word). A significant 
number of names (61.3%) failed to comply with 
the Portuguese phonologic system (related to the 
sound of words) and/or the spelling system (relat-
ed to the written form of words)  contained more 
than one word, comprised a high proportion of 
infrequent syllable types or stress patterns and 
included abbreviations. The results suggest that 
some of the brand names of Portuguese medication 
should be reevaluated, and that regulation on this 
issue should be enforced and updated, taking into 
consideration specific linguistic and spelling codes.
Key words  Commercial medication brand names, 
Qualitative analysis, Language, Linguistics, Med-
ication legislation
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Introduction
The names of medicinal products must be clear, 
legible and not associated with information of a 
promotional nature, thus ensuring their safe use 
and avoiding medication errors1,2. Preferably, 
these names should not contain2-4:
. abbreviations, which might be ambiguous, 
unfamiliar, or unknown (and thus opaque) to the 
patients, pharmacists and/or prescribers,
. adjectives (e.g. ‘rapid’, ‘hiper’ in Portuguese 
or ‘hyper’ in English, etc.), which might suggest 
the existence of enhanced medicinal proprieties, 
. symbols (e.g. ‘+’), which might also be am-
biguous or misleading and, words with hyphens, 
because hyphens increase word extension and re-
flect morphologic or structural complexity5.
Considering the Portuguese regulation2 the 
names of medicines may be classified according 
to one of the three following groups: 1) names of 
fantasy, 2) the common designation of the drug 
followed by a brand, or 3) the common desig-
nation of the drug followed by the name of the 
applicant or the Marketing Authorization Hold-
er. In particular, “the fantasy name corresponds 
to a term without a proper meaning, fruit of 
the imagination, devoid of correspondence in 
the reality, which objective is only to allow the 
production of sounds based on the reading of 
certain combinations of letters.” In this context, 
the brand names of medicines correspond to the 
group 1 - names of fantasy, the names of branded 
generics medicines correspond to group 2 - the 
common designation of the drug followed by a 
brand; and the names of the generic medicines 
correspond to group 3 - the common designa-
tion of the drug followed by the name of the ap-
plicant or the Marketing Authorization Holder2. 
Also, in accordance with the Portuguese regula-
tion (Law Decree 176/2006, article 3, available at: 
http://portalcodgdh.min-saude.pt/images/c/cf/
DL176-2006.pdf), “a medicine is any substance 
or associations of substances with preventive or 
curative proprieties on human diseases or on 
their symptoms through exerting a pharmaco-
logical, immunological or metabolic action to 
restoring, correcting or modifying physiological 
functions, or that might be used or administered 
in humans to establish a medical diagnostic.”
In general, medicine brand names should be 
formed by just a single word2,4, thus making it 
easier to recall1. Despite the fact that there are re-
ports cited in health written materials of patient 
deaths as a consequence of misunderstandings 
related to the interpretation of abbreviations6, 
according to some regulation their use might be 
acceptable in medicine brand names when they 
provide additional information on the charac-
teristics of the medicinal product (e.g. route of 
administration)2,7. The regulation on the formal 
characteristics of medicine brand names, such as 
those from the National Medicines Agency IN-
FARMED, I.P. – Autoridade Nacional do Medica-
mento e Produtos de Saúde, I.P. (the Portuguese 
medicine authority of medicines and health 
products)2, the European Medicines Agency7, or 
the Australian Medicines Agency8, does not in-
clude any specific recommendation on the ad-
equate number or types of syllables, letters, or 
other characters (e.g. symbols). However, the 
Food and Drug Administration (FDA) (the Unit-
ed States Department of Health and Human Ser-
vices agency that among other is also responsible 
for assuring the safety and efficacy of the medi-
cines) is somewhat more specific in this respect: 
(a) the applicant or sponsors are encouraged to 
provide a written transcription of the intended 
pronunciation of the brand (e.g. using the pho-
netic alphabet, that is an alphabet internationally 
accepted to transcribe all sounds/languages in 
non-ambiguous way, which might be consulted 
in the following link https://www.langsci.ucl.
ac.uk/ipa/IPA_chart_(C)2005.pdf), because this 
might impact on how the names are pronounced 
in practice, to promote their precise identifica-
tion and the prevention of medication errors, 
and (b) modifiers (e.g. abbreviations) need to 
be explained/detailed, because their use might 
suggest different meanings to health profession-
als or patients. Furthermore, the FDA critically 
reviews all proposed names, for instance using 
databases and computational linguistic methods 
to evaluate similar spellings, and orthographic or 
phonological similarities, that are similarities re-
lated to the written or sound form of the words, 
respectively. In these evaluations, attributes are 
screened such as: identical prefix (the use of an 
affix at the beginning of a word), infix (the use of 
an affix inside the word), suffix (the use of an af-
fix at the end of a word), length, stress, and num-
ber of syllables9. The affix might be considered a 
segment (or a specific part of a word) that act as 
a modifier5,9. 
The length of brand names, for instance, is 
a fundamental issue for their development and 
conception. In general, short names are more 
easily spelled, pronounced and recalled (e.g. 
names with 4 or less letters in the case of English 
words, as tall, ball call, etc.). Nevertheless, over-
ly short names are also not advisable, because 
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these words are more likely to present common 
sounds or similar orthographic parts (e.g. pho-
nological neighbors, which are words containing 
at least one common sound/part, such as Actos® 
and Actonel®4,10-13. According to Lambert et al.14, 
32,748 names of branded medicines from a data-
base of medicines marketed in the United States, 
contained an average of 1.7 words, 3.5 syllables, 
and 10.3 letters (SD = 6.74). Another source re-
ports that the most common US brand names 
comprised 8 letters12. Word size in number of let-
ters has been shown to impact on subjects’ word 
recognition. This has been shown for instance in 
the English Lexicon Project (ELP). ELP is a mul-
ticenter study that among other aims to collect 
a large number of data on behavioral tasks with 
words and non-words and that enrolls present-
ly six testing Universities (http://elexicon.wustl.
edu/). In this project, 33,006 words (with 3 to 13 
letters) were evaluated and 816 participants were 
enrolled in a lexical decision task, that is an ex-
perimental task in which the participants had to 
recognize different words15,16. Results from this 
study support that, irrespective of the lexical fre-
quency (the probability of using a word in a cer-
tain language), the number of syllables, and the 
number of neighbors (different names that are 
almost identical in terms of their sound form), 
the accuracy and reaction time in the recognition 
of words correlate with the number of letters 
of the word. In particular, an inhibitor effect in 
word recognition was detected on words with 8 
to 13 letters, with these words taking longer to be 
recognized than shorter ones15. In another study 
(140 participants), specifically conducted on 
Portuguese, three disyllabic words (words with 
two syllables), as tema in Portuguese (syllabic 
division: te.ma) or ‘theme’ in English, and three 
trisyllabic words (words with three syllables), as 
tomada in Portuguese (syllabic division: to.ma.
da) or ‘capture’ in English, were tested, in an au-
ditory and oral task (first the words were orally 
produced and then the participants had to orally 
reproduce all their segments or sounds). It was 
found that longer words were more prone to be 
orally produced with errors: 46% of the disyllab-
ic words were orally produced correctly vs. 30% 
of the trisyllabic words17.
Discrepancies between the general sound 
patterns of the language and the sound patterns 
found in medicine brand names may also in-
crease readability problems. There are a number 
of properties that characterize words in Europe-
an Portuguese. In what follows we describe some 
basic features of the language that will allow us 
determining the extent to which medicine brand 
names may deviate from the common sound pat-
terns found in European Portuguese words.
In European Portuguese, word stress may oc-
cur in one of the three final syllables in a word18,19. 
Depending on stress location, words are classified 
as: (a) oxitone (stress on the last syllable), (b) par-
oxitone (stress on the penultimate syllable) and, 
(c) proparoxytone (stress on the antepenultimate 
syllable)19-21. Portuguese words with penultimate 
and final stress are more frequent than words 
with antepenultimate stress (74% and 22.8% vs 
3.2 %, respectively)20. Importantly, word stress is 
a fundamental issue to the appropriate process-
ing, understanding, and intelligibility of speech, 
as has been shown in several studies on stress 
patterns22,23. For example, in a recognition task of 
spoken English words, it was found that both na-
tive (English-speakers) and non-native English 
speakers (Dutch speakers) used stress patterns to 
identify the relevant words22. 
Other basic linguistic features that influence 
how words are processed, read, or written, in-
clude: (a) the phonetic segments, or the elemen-
tary sounds of the language, that compose words, 
such as consonants (C), vowels (V), nasals (N) 
(vowel and vowel-like sounds that are produced 
with nasal resonance) and glides (G) (vowel-like 
sounds that must occur with a vowel that func-
tions as a syllable nucleus) and (b) the patterns 
of combinations of sounds within the syllables 
the patterns of combinations of sounds within 
the syllables that compose words – e.g. the Portu-
guese word medicamento in Portuguese or ‘med-
icine’ in English is formed of 5 syllables (syllab-
ic division: me.di.ca.men.to), but only 2 syllable 
types, 4 of the type CV (me, di, ca and to) and 1 
of the type CVN (men)5,24,25. 
The frequency of segments and syllable types 
may influence word processing. For instance, 
in studies involving word naming and lexical 
decision tasks, it has been found that words in-
cluding more frequent syllable types were recog-
nized faster than words with less frequent types 
of syllables24,25. In European Portuguese, like in 
other languages, segments (for the most of the 
categories C and V) are grouped into syllables 
depending on their sound properties. Some rare 
consonantal sequences constitute ill-formed 
consonant clusters, and they trigger the insertion 
of a vocalic position (a V-Slot). This vocalic po-
sition allows segments to be parsed into syllables 
that conform to the language general laws for syl-
lable formation. For example, while a consonant 
cluster like tr yields a well-formed syllable in Por-
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tuguese (as in the word dentro in Portuguese or 
‘inside’ in English, which is syllabified as den.tro), 
a consonant cluster like ft in the Portuguese word 
afta or ‘aphthous stomatitis’ in English yields a 
ill-formed syllable structure (because in the Por-
tuguese sound system ft cannot start a syllable, 
as in a.fta, and f cannot close a syllable either, 
as in af.ta). In the latter type of cases, a vocalic 
position emerges between the two consonants (a 
V-slot). V-slots allow the syllabification of words 
containing problematic consonant sequences, as 
in a.fV.ta, which then exhibits the typical syllabic 
pattern of the language (the pattern where sylla-
bles are formed of one consonant and one vowel, 
which is the most frequent syllable type in Portu-
guese)19. As a result, the word afta may be realized 
as afeta (or, to be more precise, [ˈafɨtɐ] using the 
international phonetic alphabet). 
The frequency of V-slot in available corpora 
of European Portuguese (or databases of texts of 
common language), such as the TQT (comprises 
22994 words) and TA90PE11 (comprises 64757 
words), is very low, corresponding to 0.07% and 
0.2%, respectively. Both the corpus TA90PE and 
TQP are formed by common words, since the first 
is the result of the transcription of colloquial in-
terviews from the different regions of Portugal, 
and the second is formed by transcriptions of oral 
samples collected in the Terra Quente Transmon-
tana (a region in the North of Portugal)18,26. What 
is important for us here is that the presence of a 
V-slot in a word indicates that a given consonantal 
string is rare and phonologically problematic18,26. 
Rare syllable types in European Portuguese 
include VG or CVGC. For instance, in the corpora 
just cited, these syllable types have been reported 
to account for only 1.51% and 1.21% of the total 
number of occurring syllables, respectively. 
Importantly, above 90% of syllables found in 
Portuguese corpora belong to a very small subset 
of syllable types, composed of only 10 syllables 
types (including CV, CVC, CCV)27.
Using a large sample of Portuguese medicine 
brand names, the purposes of this study were:
1. to investigate the compliance/agreement of 
medicine brand names with Portuguese regula-
tion,
2. to characterize some of their basic linguis-
tic and orthographic features, 
3. to compare their basic linguistic features 
with reference frequency values of common 
language, thus assessing the extent to which the 
form of medicine brand names may deviate from 
the most common sound patterns found in Eu-
ropean Portuguese.
Method
A random sample of Portuguese medicine brand 
names was obtained from the Portuguese pre-
scribing guide28. Approximately 25% of all med-
icine brand names available in this guide (531 
brand names) were randomized, of which 57 
were excluded for either being repeated (to avoid 
redundant analysis), or for comprising inter-
national nonproprietary names or the generic 
names used worldwide (to assure that only brand 
names were included in this study). The main 
reasons for not selecting generic names were the 
following: (a) generic and brand names present 
different structures, because generic names are 
formed by international nonproprietary names 
in association with the name of the market-
ing authorization holder and brand names are 
formed by invented names2, and (b) linguistic 
and orthographic rules are already available to 
adapt to Portuguese the names of generic med-
icines that are internationally marketed29,30. For 
instance, for the translation of the name of active 
substances (e.g. generic names) the American As-
sociation of Physicians recommends: the use of i, 
t, f and e instead of y, th, ph and ae respectively, 
and to avoid k and w29. These rules are very simi-
lar to those of the World Health Organization30,31, 
and they are respected in the translation of Por-
tuguese generic names which follow these gener-
al rules (e.g. the i is used instead of y, in the case 
of ‘hydrocortisone’ in English vs. hidrocortisona 
in Portuguese)30. Consequently, it was considered 
that the name of generic medicines should be 
studied in an autonomous investigation. 
The assessments of the legal requirements 
were based on the criteria set out in the pharma-
ceutical regulation(e.g. names should comprise 
only one word and preferably not contain abbre-
viations)2,7,8.
The medicine brand names were manual-
ly classified into 4 groups: Group 1 comprised 
names that might be considered as not being 
written in accordance with the orthographic 
system of European Portuguese32, Group 2 com-
prised names not written in accordance with 
that system, while Group 3 and 4 comprised 
names written in accordance with that system. 
This classification was performed taking into 
account the new Portuguese orthographic rules, 
given the inclusion of the letters k, y and w, as 
belonging to the Portuguese alphabet. However, 
it is important to highlight that these new rules 
only started to be mandatory for Brazil in 2009 
and in Portugal they will only become mandato-
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ry in 2016 (www.portaldalinguaportuguesa.org/
acordo.php). These three letters (k, y and w) were 
introduced in the Portuguese alphabet essential-
ly because of the large scale introduction in the 
language of proper names and loan words from 
English origin (as currently happens in other 
languages of the world as well). In general, the 
use of these words only represented a very limit-
ed part of the Portuguese corpora. For instance, 
this can be seen searching the corpus CETEM-
Publico (a database with190 millions of words 
and specifically formed by journalistic texts, free-
ly available at www.linguateca.pt/ACDC, where 
words like ‘Hollywood’ or ‘Gulbenkian’ clearly 
display a deviant orthographic shape). Given 
this, Group 1 includes names containing letters 
that were not part of Portuguese alphabet until 
recently (k, y, w). Group 2 includes names con-
taining combinations of letters not allowed in 
the European Portuguese orthographic system 
(e.g. strings with double letters such as tt or zz, 
or ending with consonants different from r, l, s, 
m, n or x, such as t or d, and so forth). Group 
3 includes names written in accordance with the 
European Portuguese orthographic system and 
excluding the names that comprise the letters k, 
y and w (in accordance to the rules of the pre-
vious orthographic convention legally approved) 
and Group 4 includes names integrating rare seg-
ments, such as names ending in n or x, or names 
containing V-slots (names containing unusual 
sequences of consonants such as ft)27.
It was pre-defined that if a name were to cu-
mulatively comprise the letters k, y and w (Group 
1), combinations of non-canonical segments or 
combinations of letters non-existent in Portu-
guese (Group 2) and/or end in n or x or contain 
V-slots (Group 4), this name would be assigned 
as an element of Group 1, and that if a name 
were to cumulatively comprise combinations of 
non-canonical segments (Group 2) and/or end 
in n or x, or contain V-slots (Group 4), this name 
would be assigned as an element of Group 2. In 
both situations the names were classified in ac-
cordance to the situation that was considered as 
more deviant from the natural Portuguese pat-
terns. 
The variables studied are described in Chart 
1, where the frequency of the type of syllables was 
also quantified. For our purposes, syllable types 
were classified as frequent or rare. The 10 more 
frequent syllabic of the Portuguese European re-
ferred to in the introduction section are the fol-
lowing CV, V, CVC, CVGN, CVN, VC, CVG, VN, 
CCV and VG26,27. For the purpose of the present 
study, syllable types were classified as frequent if 
they belong to the set of the ten most frequent 
syllable types in European Portuguese, or rare is 
they are not part of that set27.
The linguistic variables 1 and 3 to 6 were 
quantified using the informatics tool FreP – Fre-
quency Patterns of Phonological Objects in Por-
tuguese33. Given the algorithm used in this tool 
(a) the individual stress patterns of all the words 
that constituted the brand names were classified 
in accordance with the natural pronunciation 
patterns of Portuguese, therefore the possible ex-
istence of alternative non-Portuguese stress was 
not investigated – the rational here is that, by de-
fault, Portuguese users will pronounce medicine 
brand names following the general rules of the 
language for stress placement; (b) the letters y, 
k and w were respectively processed as i, c and 
v; and (c) the doubling of letters that does not 
exist in Portuguese was processed as just one 
letter, for instance tt was processed as t, because 
this corresponds to the way these letter sequences 
are pronounced by default. This way, none of the 
non-canonical names (foreign names not adapt-
ed to Portuguese) were analyzed in accordance to 
the phonologic and orthographic rules of others 
language. The options (a), (b), and (c) reflect the 
average European Portuguese reader, given that 
41% of the Portuguese population self-report 
not to speak any other language34: the Portuguese 
population is assumed to follow the natural pho-
nological patterns of their native language when 
reading medicine brand names. 
We should notice that European and Brazil-
ian Portuguese present different phonologies. 
Thus, words may be read with different pronun-
ciations and reference values for the frequency 
of occurrence of segments, syllables and stress 
patterns may also vary. Therefore, the results we 
report here cannot generalize to other varieties 
of Portuguese. We believe a specific evaluation of 
medicine brand names used in Brazil similar to 
the one developed here would be recommended.
MS Word 2010 for Windows 7 was used to 
quantify the number of: (a) letters (variable 2), (b) 
words with a hyphen (variable 7), and (c) expres-
sions or words not allowed according to regulatory 
requirements (variable 9), applying the automatic 
search function of this program. Names contain-
ing abbreviations, numbers, or symbols (variable 
8) were manually identified. Abbreviations may 
be classified as acronyms (or abbreviations sus-
ceptible of being read as a single word, e.g. PA, 
which English full correspondence is ‘pressure 
aerosol’ - see http://www.oxforddictionaries.com/
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definition/english/acronym) or initialism (or an 
abbreviation susceptible of being read by pro-
nouncing the initial letters, e.g. FML, which En-
glish full correspondence ‘fluorometholone’ – see 
http://www.oxforddictionaries.com/definition/
english/initialism)35. Thus, a qualitative analysis 
to distinguish between acronyms and initialisms 
was performed (Chart 1). This classification was 
done in the following way, one of the researchers 
read all abbreviations (acronyms or initialisms) 
and immediately after classified the abbreviation 
as an acronym or as an initialism. One expert in 
linguistics re-checked all the linguistic data, using 
the same procedure.
The occurrence of abbreviations in the names 
of prescription medicines and over-the-counter 
medicines (OTC) was specifically quantified 
and analyzed. This quantification was consid-
ered pertinent, because OTC might be acquired 
without the direct intervention of a health pro-
fessional36,37, and this may increase the potential 
for problems originated from the presence of ab-
breviations in medicine brand names.
Despite the recommendation to not use ab-
breviations in medicinal information, such as 
package leaflets, when they are used their full 
meaning should correspond to the official lan-
guage of the country where the medicine is 
marketed (e.g. CR or ‘Controlled-Release’ for 
English)38. In addition, according to some regu-
lation the use of abbreviations in medicine brand 
names might be acceptable if they add informa-
tion about the medicine (for instance, the abbre-
viation S in the case of the medicine Kompen-
san S®, might be considered useful for patients 
and health professionals, as a way of noticing the 
presence of a particular substance; Simethicone, 
in this medicine)2,7. For this reason, the following 
aspects were checked by a pharmacist: (a) pres-
ence/absence of the full meaning of abbreviations 
Chart 1. Variables studied.
Number of
1 - Orthographic words (Tokens)
2 - Letters
3 - Syllables
4 - Syllable types
5 - Consonants, vowels, glides, 
and V-slots
6 - Words per stress position
7 - Hyphenated words
8 - Words containing abbreviations 
(acronyms or initialims), numbers 
or symbols
9 - Expressions or  words 
not allowed according to the 
regulatory requirementsb
Method
FreP
MS Word
FreP
FreP
FreP
FreP
MS Word
Manual
MS Word
Objective(s)a
1, 2, 3
2, 3
2, 3
2, 3
2, 3
2, 3
1, 2, 3
1, 2, 3
1
Citation(s)
(Handler et al., 2004; Infarmed, 2012; 
Institute for safe medication practice, 
2011)1,2,4
(Lambert et al., 2005)12
(Food and Drug Administration, 2010; 
Vigário, Martins, & Frota, 2006)9,26
(Vigário, Martins, & Frota, 2006)26
(Lambert et al., 2005; Mateus & Andrade, 
2000; Vigário, Freitas, & Frota, 2006)12,19,27
(Aguiar & Vigário, 2010; Food and 
Drug Administration, 2010; Mateus & 
Andrade, 2000)9,18,19
(Hyönä et al., 2004; Villalva, 2000)3,5
(Mateus et al., 2004)32
(Infarmed, 2012)2
a Objectives: 1. to investigate the compliance of medicine brand names with regulations; 2. to characterize their basic linguistic 
features, and 3. to compare the values of their basic linguistic features with reference values for the language. b e.g. ‘rapid’, ‘hiper’.
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in the content of the package leaflet, and (b) pres-
ence/absence of abbreviations corresponding to 
a language other than Portuguese.
The full meaning of abbreviations was con-
firmed in the package leaflet, when present. In 
the cases where the full meaning of an abbrevia-
tion was not described in the package leaflet, the 
information was obtained in the official sites for 
medical abbreviations such as Medilexicon39 for 
English abbreviations, or in the glossary of the 
National Prescribing Guide for Portuguese ab-
breviations28. It was important to verify the full 
correspondence of English abbreviations because, 
contrary to what would be expectable, abbrevia-
tions with full correspondence in English were 
also found within the brand names of Portuguese 
medicines. The package leaflets were consulted 
using a public Portuguese data base: the Infomed 
(available at https://www.infarmed.pt/infomed/
inicio.php)40.The full meaning of abbreviations 
was not checked on the outer package of the re-
spective medicines, because of economic and lo-
gistic constraints that restricted access to such a 
large number of packages. 
Results
Distribution by the 4 classificatory groups
Overall, 24.3% of the names (115 of 474 
names) were not written in accordance with 
the Portuguese orthographic system (Group 2). 
These names comprised non-canonical segments 
(or combinations of letters non-existent in Portu-
guese), such as the segments tt or ll, or the names 
ending in t, d or c (e.g. Nicotinell®, Novynette®, 
Atrovent®, Ronic® and Sinecod®). Also, 10.8% 
included the letter(s) k, y or w (e.g. Daktacort®, 
Alorexyl®, and Twinrix®) (51 of 474 names) 
(Group 1). Data are presented in Figure 1.
Names ending with t, d, and c were the most 
common in Group 2 (37.4%; 43 cases out of 
115 names). Names ending in n were the most 
prevalent in Group 4 (63.7%; 79 cases out of 125 
names). This group comprises names with rare 
structures in Portuguese, such as, the names end-
ing in n (e.g. Rocephin®) or x (e.g. Dostinex®). 
In the group of names comprising the let-
ters k, y and w (Group 1), 8 names ended in n, 
7 names contained more one letter of the type 
k, y or w, and 5 comprised V-slots. In the group 
of names containing non-canonical segments (or 
combination of letters that do not exist in Por-
tuguese) (Group 2), 9 names ended in n, and 9 
names comprised V-slots. The names were differ-
ent in every case.
Among the 474 names: 384 (81%) were 
formed by one orthographic word, 64 (13.5%) 
by two words, and 89 (18.7%) by more than two 
words. A few names with 4, 6, and 9 orthograph-
ic words were also identified. Overall the 474 
names comprised 615 words. The distribution of 
the number of words per name is presented in 
Figure 2.
1
10,8
2 3 4
51
24,3
115
38,8
184
124
26,2
1 - Names containing the letters k, y and w
2 - Names containing non-canonical segments
2 - Names written in accordance with the Portuguese 
orthographic system
4 - Names containing structures of low frequency in 
Portuguese
%
number
Figure 1. Percentage and names distributed by groups.
one
two
three
four
six
nine
Figure 2. Percentage of the number of words in 
medicine brand names.
0,2%81% 14% 4% 0,2%1%
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Word length: number of orthographic 
words, letters and syllables
The brand names contained 2 to 25 letters, of 
which 70.6% had 6 to 9 letters. Median of 8 and a 
mean of 8.7 (SD = 3.2) letters per name. 
The average number of syllables per brand 
name was 3.7 (SD = 1.5). Among the 615 or-
thographic words that formed the 474 names, 
96.1% contained 4 or less syllables, 11.4% a sin-
gle syllable, 3.9% contained between 5 and 7 syl-
lables and none contained more than 8 syllables.
Syllable types, segments, and V-slots
The ten most frequent syllable types in Eu-
ropean Portuguese explain the syllabic structure 
of almost all brand names (93.2%; 1,649 of the 
1,769 syllable occurrences). 116 names (24.5%) 
comprised at least one rare syllable type. Over-
all, 120 rare syllable types were identified: 13 
(10.8%) in the names of Group 1, 28 (23.3%) in 
the names of Group 2, 29 (24.2%) in the names 
of Group 3, and 50 (41.7%) in the names of 
Group 4.
The 474 names were formed by 4,066 seg-
ments (with an average of 9 segments per word; 
SD = 3). The number of segments was deter-
mined by the sum of the number of consonants, 
vowels, and glides. The percentage of V-slots (n = 
39, 2.2 %) was calculated in relation to the total 
number of syllables (n = 1,769), as a way of con-
stituting an indicator of their occurrence. Data 
are presented in Table 1.
Number of words per stress position
The sum of words with final (385), penulti-
mate (155) and antepenultimate stress (5) was 
545. In general, final stress was predominant 
(70.6% of 545), when compared to penultimate 
(28.4% of 545), and antepenultimate (0.9% of 
545) stress. 
Hyphenated words
Hyphens were identified in 4.2% of names. 
A name with 2 hyphens was also found (Ben-u-
ron®).
Names containing abbreviations, numbers 
and symbols, and abbreviations 
full meaning
Thirty-six brand names (7.6% of 474) con-
tained abbreviations and in one case two abbre-
viations were found in a single name, hence 37 
abbreviations were identified: 4 belong to OTC 
names, 3 might be read as acronyms, with the re-
maining being read as initialisms, and 8 present 
full correspondence in English instead of Portu-
Total number of syllables     
(more frequent + rare)
Ten most frequent syllabics types
CV 
V 
CVC 
CVGN 
CVN 
VC 
CVG 
VN 
CCV 
VG 
Total (more frequent)
Rare syllable types
VGC
CCVC
CCVCC
CCVG
CCVN
CGVC
CGVN
CVCC
CVGC
VCC
Other rare
Total (rare)
Segmentsa and V-slots
Consonants
Vowels
Glides 
Total
Segments average
Standard Deviation
V-Slotb
Number of 
occurrences
1769
863
147
393
5
58
36
8
27
108
4
1649
1
34
9
1
13
2
1
52
2
1
4
120
2313
1730
23
4066
9
3
39
%
100
48.8
8.3
22.2
0.3
3.3
2
0.5
1.5
6.1
0.2
93.2
0.1
1.9
0.5
0.1
0.7
0.1
0.1
2.9
0.1
0.1
0.2
6.8
56.9
42.5
0.6
100
2.2
Table 1. Distribution of syllable types, segments, and 
V-slots in medicine brand names.
C: consoants; V: vogals; G: glides; N: nasal.
a Segments = consonants + vowels + glides. b V-slots 
percentages were calculated in relation to the total number of 
syllables (n = 1769).
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guese. In only 3 cases was the full meaning of the 
abbreviations described in the package leaflets. 
With respect to the presence of numbers and 
symbols, 6 brand names contained numbers in 
their structure (1.3% of 474 names) and 1 brand 
name enclosed a symbol, namely ‘+’ (see Chart 2).
Prohibited expressions  
Eight prohibited expressions2 were detected in 
21 brand names (Chart 2).
Discussion
Letters only recently introduced 
to the Portuguese alphabet 
and non-canonical segments
In the present study, the occurrence of names 
with letters k, y and w or containing non-canon-
ical segments (associations of letters that are 
non-existent in Portuguese, such as tt), was quite 
prevalent, affecting almost half of the names. Giv-
en that it is well documented that the mental pro-
cessing of words is dependent on an orthograph-
ic and phonological code (respectively related 
Chart 2. Abbreviations, names and expressions not recommended/allowed.
Abbreviations included specifically in names of over-
the-counters medicines
Abbreviations that might be read as acronyms
Abbreviations with full correspondence not given in 
Portuguese
Abbreviations with full description in the package 
leaflet text
Names comprising numbers
Names comprising symbols
Names comprising prohibited expressions
C = vitamin C
S = simethicone
DM = diethylamine
R = hoarseness
CA = continuous ambulatory
PA = pressure aerosol
LA = long action
CR = controlled-releases
PA = pressure aerosol
CPAD = continuous ambulatory peritoneal dialysis
OD = once daily
SR = slow releases
LA = long action
MR = muscule relaxant
DC = direct current
CAPD = continuous ambulatory peritoneal dialysis
M3 = mixture three
B = polybacterial lysates
‘HBO 12®’
‘Q10®’
‘Cerbon-6®’
‘Debridat 200®’
‘HUMULIN M3®’
‘CAPD/CAPD 17®’
‘Depot Medrol + Lidocaine®’
‘rapid’
Forte or ‘Strong’a
‘Plus’
Hiper or ‘Hyper’ a
Pediátrico or ‘Pediatric’a
Infantil or ‘Infant’a 
Adulto or ‘Adult’a
Junior or ‘Younger person’a
a  The Portuguese word in italic and the correspondent translation between quotation marks.
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with the written or oral forms of the words)41,42, 
this type of letters and segments might have a 
negative impact on the adequate memorization, 
recall and pronounceability of words, and conse-
quently not be suitable to form brand names for 
medicines to be used by the Portuguese speaking 
population. In Portuguese, orthography presents 
a close correspondence to the sound, i.e. each let-
ter corresponds to one sound. The specific cases 
of names containing double letters, usually con-
sonants (e.g. tt or zz), seems to increase reading 
complexity: not only these cases deviate from the 
orthographic rules of the language, but they are 
formed of more letters than those required, since 
two characters represent single sound. Overall, 
the fact that these orthographic patterns were 
different from those that the readers are famil-
iar with might cause doubts as to the way words 
are correctly read, written or pronounced. In this 
context, brand names that cumulatively include 
linguistic features from different groups (e.g. 
names containing letters recently introduced in 
the Portuguese alphabet, such as the k, y and w 
plus non-canonical segments) are likely to be 
more complex and processed more poorly.
Number of orthographic words 
A considerable number of names included at 
least two orthographic words. This might neg-
atively influence their adequate pronunciation 
and memorization1,2,4,8,12,14,43.
Word length: 
number of letters and syllables
Most of the names in this study contained up 
to three syllables, a pattern of distribution also 
found in the common/colloquial Portuguese, 
such as that represented in the TQP and TA90PE 
(see the introduction)26,27. Thus, the word length 
patterns of the brand names also were very simi-
lar to those of others names available on Europe-
an Portuguese databases corpora26,27.
Although the average length of Portuguese 
brand names seems appropriate, as far we known 
there are no studies specifically on the appropri-
ate length of Portuguese brand names. Therefore, 
it would be desirable to confirm the suitability of 
the brand names length before their marketing 
approval (e.g. through using experimental stud-
ies). A number of facts suggest, nevertheless, 
that the average length of the Portuguese brand 
names may be appropriate: 1) the brand names 
slightly longer than the average Portuguese 
words (or the names with 3 or 4 syllables)26,27, are 
possibly more appropriate to feature on the outer 
packaging and to use within the text of the pack-
age leaflets, because presumably these names 
will be better distinguished and less confusable, 
2) overly long names (namely names with more 
than 4 syllables) are not advisable so as to assure 
their adequate memorization, recall and pronun-
ciation10-12, because longer words take more time 
to be identified (e.g. in reading tasks)44, and 3) 
too short names (or the names with less than 3 
syllables) are also not advisable, because they are 
usually related with a greater number of phono-
logical neighbors (different names that are al-
most identical in terms of their sound form)45. 
This situation probably increases the possibility 
of correspondences with other words and there-
fore the risk of confusion between similar names 
of medicines. 
The Portuguese medicine brand names ex-
hibit an average size in terms of number of letters 
and syllables very similar to those described in 
studies involving names of medicines marketed 
in other countries14. This was not surprising giv-
en that many of these medicines were also avail-
able in other countries with the exact same name, 
consequently confirming that it is very likely that 
these names were not initially invented/devel-
oped in Portuguese speaking countries46. 
Syllable types, segments, and V-slots
The predominance of the ten most frequent 
syllable types in European Portuguese27 appar-
ently confirms the existence of some similarity 
between the structure of brand names and the 
general Portuguese words. Nevertheless, it was 
possible to identify in the brand names a high 
proportion of syllable types that are rare in Por-
tuguese (e.g. CVCC and CCVC)27. As expected 
the rare syllable types were much more prevalent 
(almost twice as many) in the group of names 
containing structures of low frequency, such as 
the names ending in n or x, because these devi-
ant structures will indirectly promote the forma-
tion of rare syllable types. Again, deviant syllable 
structure might yield lower readability of some 
Portuguese medicine brand names. 
A high prevalence of vowels and consonants 
was found in the sample of names, similar to 
those in other European Portuguese corpora (or 
databases of texts that are used to estimate the 
frequency of words, segments, letters, symbols, or 
punctuations signs in a certain language)18,26. By 
contrast, a lower proportion of glides and a great-
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er proportion of V-slots were found in relation 
to the common patterns. For instance, the seg-
ments were distributed as follows: 48% vowels, 
46% consonants, 5.8% glides, and 0.2% V-slots 
in the corpus TAP90PE (22,994 words) (we recall 
that these are rare elements that emerge to break 
sequences of segments that do not form proper 
syllables in the language, as dv in the Portuguese 
word advogado or ‘lawyer’in English)18. Assum-
ing that V-slots, only emerge with segmental se-
quences that are not allowed by the general laws 
of the language for the combination of segments, 
the proportion of V-slots found in brand names 
also suggests the low readability of some Portu-
guese brand names.
Stress distribution 
The frequency of the three stress patterns in 
the medicine brand names under observation 
was clearly different from that commonly found 
in the language18,26. In fact, in our data words 
with final stress were more prevalent than words 
with penultimate stress. As we have seen in the 
introduction section, according the data available 
in a reference database of Portuguese, words with 
penultimate stress are more frequent than words 
with final stress (22.8%) and antepenultimate 
stress (3.2%), and similar results have been re-
ported elsewhere18,20,26. 
Despite the proportion of the three stress pat-
terns being clearly different from those in com-
mon language, it is not expected that this should 
produce a very significant negative impact on 
the readability of names, because the words with 
stress on the last syllable are also fairly common 
in Portuguese.
Names containing hyphenated words 
The proportion of words with a hyphen was 
very limited in the sample of brand names. This 
seems to be a good result, given that the presence 
of hyphens increases word extension and cor-
relates with a higher morphological complexity, 
since they indicate that the names are formed by 
associations of two or more words (as in arco-íris 
in Portuguese or ‘rainbow’ in English). Therefore 
the use of hyphenated word in medicine brand 
names probably also negatively impacts on their 
readability3,5. 
Names containing abbreviations
Various abbreviations were identified in the 
sample of brand names, although their use is 
not recommended1,2,4,12. Additionally, many of 
these abbreviations referred to English technical 
terms (e.g. CR meaning ‘controlled-release’ or PA 
meaning ‘pressure aerosol’), which might repre-
sent an additional issue to Portuguese monolin-
gual speakers, and also to non-health profession-
als who are usually not familiarized with the use 
of technical terms. Unexpectedly, in many cases 
the full meaning of each abbreviation was also 
not detailed in the text of package leaflets. There-
fore names containing abbreviations might be 
considered less readable and in some cases com-
promise the safe use of medicines6,47.
In the case of OTC medicines, exceptionally 
some abbreviations used in their names might 
be considered compliant with the legal require-
ments, as a result of their potential advanta-
geous2. For instance: (a) in the case of Aspirin 
C® and Kompensan S®, the C and S probably 
promote a better differentiation relative to oth-
er medicinal products with similar names (As-
pirin® and Kompensan®, respectively) or allow 
the composition of the medicine to be better 
identified, (b) in the case of Mentocaina-R®, the 
R (rouquidão in Portuguese or ‘hoarseness’ in 
English) constitutes a cue to identify one of the 
symptoms that the medicine treats, and (c) in the 
case of DM, the DM (dores musculares in Portu-
guese or ‘muscle pain’ in English) might also be 
associated with the treatment of a specific health 
issue. However, if the patients do not have any 
previous knowledge about the medicine, the use 
of these abbreviations is not likely to be benefi-
cial, because they will not be able to assign any 
meaning to these abbreviations. 
The fact that almost all abbreviations identi-
fied in this study were acronyms, presents even 
more readability problems, because the pronun-
ciation of initialisms is easier than that of acro-
nyms34.
Names containing numbers and symbols 
Some names were identified comprising 
numbers or symbols in this study. Although their 
use is not recommended because of the risk of 
patients’ misinterpretation and low readabili-
ty2, it is possible to identify some possible pos-
itive reasons for their use: (a) it may facilitate 
patients’ memorization and recall of medicine 
brand names by increasing their phonological 
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extension – in other words, the oral form of the 
name is longer than the correspondent oral form 
in the case of the symbol being omitted (e.g. 
Cerbon-6® is read as Cerbon-seis in Portuguese 
or ‘Cerbon-six’ in English; ‘+’ is read as mais in 
Portuguese or ‘more’ or ‘plus’ in English); or (b) 
it may promote the distinction between similar 
brand names (e.g. the use of M3 probably helps 
to better distinguish between different types of 
Humulin® insulins). By contrast, their use might 
also be associated with negative reasons such as 
increasing the complexity of medicinal brand 
names, as well as constituting an element of 
promotional nature (e.g. if their use increases 
the memorization of medicine brand names in 
particular by healthcare prescribers). Overall the 
use of numbers and symbols in medicine brand 
names for possible reasons of a promotional na-
ture should be adequately controlled and super-
vised by marketing authorization holders and 
health authorities. 
Names containing prohibited expressions
Also some names containing legally unac-
ceptable expressions were identified, such as 
Hiper in Portuguese (or ‘Hyper’ in English), 
‘Strong’ and ‘Plus’, also contributing to the pos-
sible existence of non-adequate names. The use 
of these expressions might (a) incorrectly suggest 
that medicines exhibit enhanced therapeutic ac-
tions, (b) influence the prescription patterns of 
physicians, or the acquisition of OTC medicines 
by patients.2 Although the expressions ‘Rapid’, 
‘Pediatric’, ‘Infant’, and ‘Adult’ are also not rec-
ommended, their use might be explained by the 
following facts: (a) in the case of insulin, ‘Rapid’ 
might facilitate the distinction from insulin with 
prolonged action and similar names, and (b) ‘Pe-
diatric’, ‘Infant’ and ‘Adult’ might facilitate the 
identification of the population group for which 
the medicinal product is intended2.
Limitations  
The formal similarity of medicine brand 
names, such as Dynapen® and Dynacirc®12, was 
not specifically evaluated, because as far we know 
there are no specific automatic tools that allow 
performing this task in Portuguese. This screen-
ing is very important, due to the risk of poten-
tial confusions between similar drug names, with 
potential harm to the patient10-13. The same type 
of screening using the names of generic products, 
medical devices, or other body-care products 
would also be advisable. 
Practical Implications 
Regulation should state/define the most ade-
quate linguistic characteristics for each language 
to assure the readability of medicines names by 
the local relevant users.
The linguistic characteristics of brand names 
are very important to the commercialization and 
marketing of medicines, because these features 
might influence the adequate memorization and 
pronunciation of brand names by health pro-
fessionals and patients. Also, the use of similar 
names might be misunderstood by patients12,14. 
Besides performing descriptive and qualitative 
studies, it is also advisable the realization of ex-
perimental studies with patients for defining the 
best word shapes for the adequate memorization, 
recall and design of brand names for each lan-
guage. Furthermore, to date there are no specific 
golden rules for developing the name of brand 
medicines in Portuguese. The suitability of med-
icine brand names for a certain speaking/read-
ing population should be investigated for each 
individual language, because linguistic rules and 
orthographic conventions vary cross-linguisti-
cally48. Similar experimental studies are also rec-
ommended to the names of generic medicines.
Software tools specifically developed to study 
the characteristics of Portuguese brand names, 
such as the automatic detection of phonological 
neighbors (different names that are almost iden-
tical in terms of their sound form), should be 
developed in order to avoid the approval of too 
similar names. The adaption of the brand names 
written in accordance with the orthographic 
system of other languages to Portuguese (e.g. 
the use of the letters k, y and w or non-canoni-
cal segments) seems also advisable, for instance 
following a procedure similar to that applied to 
the names of generic medicines (e.g. use of i, t, f 
and e instead of y, th, ph and ae respectively, for 
instance in 1) Pentoxifilina in Portuguese, that in 
English is translated as ‘Pentoxifylline’, 2) Peti-
dina in Portuguese that in English is translated 
‘Pethidine’, 3) Morfina in Portuguese that in En-
glish is translated as ‘Morphine’ and 4) Hemoco-
agulase in Portuguese that in English is translated 
as ‘Haemocoagulase’)29,30.
Although the names of brand medicines were 
specifically investigated in this study, it is like-
ly that the same or similar linguistic principles 
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might be applicable to other Portuguese brands, 
such the brands of cosmetics, medical devices, 
food, generic medicines or herbal products49,50.
Given that Portuguese is the fifth most widely 
spoken language in the world (spoken by approx-
imately 273 million people)51, the occurrence of 
the letters k, y and w, that might be used within 
non-Portuguese words or non-canonical seg-
ments in the names of brand medicines might be 
especially important, because these names might 
also be marketed in many countries other than 
Portugal, where Portuguese is also the official 
language (e.g. Brazil, Angola, or Timor). 
Moreover, the real impact of using certain or-
thographic patterns in the name of medicines is 
not completely clear/known (e.g. abbreviations/
symbols), consequently more research on the 
topic is needed. Regulatory authorities should 
be more involved in the supervision of medicine 
brand clarity and pronounceability during the 
process of medicines approval2. Besides of be-
ing involved in the creative process of inventing 
brand names, marketing authorization holders 
should assure their appropriateness.
Conclusions
Many issues were detected for the brand names 
in this study, which might promote a lower read-
ability of Portuguese brand names. Overall, some 
names were formed by more than one word or 
contained letters only recently introduced in 
the Portuguese alphabet (y, k and w), as well as 
non-canonical segments (or associations of let-
ters non-existent in Portuguese), rare syllabic 
types, V-slots (rare segments/parts of words that 
are deviant from the common patterns of the 
language), abbreviations, numbers, symbols, hy-
phenated words, and prohibited expressions ac-
cording to the pharmaceutical legislation. These 
suggest that some Portuguese brand names 
might need to be reevaluated by marketing au-
thorization holders or medicines authorities. 
Updating the pharmaceutical regulation on this 
issue is also advisable, given that the linguistic 
features of brand names are not detailed enough 
in the Portuguese and European regulation.
Collaborations
C Pires, M Vigário and A Cavaco contributed to 
the conception, design, development, analysis 
and writing-up of the manuscript.
Acknowledgments
Fundação para a Ciência e a Tecnologia, Portugal.
2582
P
ir
es
 C
 e
t a
l.
Lambert BL, Chang KY, Lin SJ. Descriptive analysis of 
the drug name lexicon. Drug Information Journal 2001; 
35(1):163-172.
New B, Ferrand L, Pallier C, Brysbaert M. Reexamining 
the word length effect in visual word recognition: New 
evidence from the English Lexicon Project. Psychon 
Bull Rev 2006; 13(1):45-52.
Balota DA, Yap MJ, Cortese MJ, Hutchison KA, kessler 
B, Loftis B, Neely JH, Nelson DL, Simpson GB, Treiman 
R. The English Lexicon Project. Behav Res Methods 
2007; 39(3):445-459.
Castelo A, Freitas MJ, Miguens F. Níveis de escolari-
dade e a capacidade de segmentação de palavras. 2010. 
[accessed 2014 July 11]. Available at: http://www.clul.
ul.pt/files/anagrama/Castelo_Freitas_Miguens_2010.
pdf 
Aguiar J, Vigário M. Contributo para o estudo da 
variação na frequência de unidades e padrões fonológi-
cos. In: XXV National meeting of the Portuguese Associ-
ation of Linguistics, 2010.
Mateus MH, Andrade E. The Phonology of the Portu-
guese. Oxford: Oxford University Press; 2000.
Frota S, Vigário M, Martins F, Cruz M. FrePOP: Fre-
quency patterns of phonological objects in Portuguese 
(version 1.0) [Database].
Pereira TA, Montero EF. Terminologia DeCS e as novas 
regras ortográficas da língua portuguesa: orientações 
para uma atualização. Acta Cir. Bras 2012; 27(7):509-
514.
Cooper N, Cutler A, Wales R. Constraints of lexical 
stress on lexical access in English: evidence from na-
tive and non-native listeners. Lang Speech 2002; 45(Pt 
3):207-228.
Soto-Faracoa S, Sebastián-Gallésa N, Cutler A. Seg-
mental and suprasegmental mismatch in lexical access. 
J Mem Lang 2001; 45:412-432.
Ferrand L, New B. Syllabic length effects in visual word 
recognition and naming. Acta Psychol (Amst) 2003; 
113(2):167-183.
Mezzomo CL, Dias RF, Vargas DZ. Fatores intervenien-
tes na produção correta da sílaba (c)vc em dados típi-
cos e atípicos de fala. Delta 2014; 30(2):353-370.
Vigário M, Martins F, Frota S. A ferramenta FreP e a 
frequência de tipos silábicos e de classes de segmentos 
no Português. In: XXI National meeting of the Portu-
guese Association of Linguistics, 2006.
Vigário M, Freitas MJ, Frota S. Grammar and frequen-
cy effects in the acquisition of prosodic words in Eu-
ropean Portuguese. Lang Speech 2006; 49(2):175-203.
Infarmed. Prontuário Nacional Terapêutico. [Nation-
al Prescribing Guide]; 2011. [accessed 2014 June 03]. 
Available at: http://www.infarmed.pt/portal/pls/portal 
/!PORTAL.wwpob_page.show?_docname=7118264.
PDF 
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Referências
Handler SM, Nace DA, Studenski SA, Fridsma DB. 
Medication error reporting in long-term care. Am J 
Geriatr Pharmacother 2004; 2(3):190-196.
Infarmed. Deliberação n.º144/CD/2012 - Norma ori-
entadora para a aceitação de nomes de medicamentos. 
[Resolution no. 144 /CD/2012 - Guiding norm for the ac-
ceptance of the medicines names]; 2012. [accessed 2014 
July 11]. Available at: http://www.infarmed.pt/portal/
page/portal/INFARMED/MEDICAMENTOS_USO_
HUMANO/AUTORIZACAO_DE_INTRODUCAO_
NO_MERCADO/144_DAM_91.pdf
Hyönä J, Bertram R, Pollatsek A. Are long compound 
words identified serially via their constituents? Ev-
idence from an eye-movement-contingent display 
change study. Mem Cognit 2004; 32(4):523-532.
Institute for safe medication practice. ISMP’S List of 
confused drug names; 2011. [accessed 2014 July 14]. 
Available at: https://www.ismp.org/tools/confuseddrug 
names.pdf 
Gonçalves C, Almeida ML. Morfologia Construcional: 
principais ideias, aplicação ao português e extensões 
necessárias. Alfa, rev. Linguíst 2014; 58(1):165-193.
Ulrich B. Preventing errors by eliminating mis-
take-prone abbreviations. Nephrol Nurs J 2007; 34(5): 
473-502.
European Medicines Agency. Guideline on the accept-
ability of names for human medicinal products processed 
through the center procedure; 2007. [accessed 2014 July 
17]. Available at: http://www.ema.europa.eu/docs/en 
_GB/document_library/Regulatory_and_procedural 
_guideline/2009/10/WC500004142.pdf
Therapeutics Goods Administration. Best practice 
guideline on prescription medicine labelling; 2011. [ac-
cessed 2014 July 11]. Available at: http://www.tga.gov.
au/industry/labelling-pm-best-practice.htm#.UxWvx-
vnV8qc
Food and Drug Administration. Guidance for indus-
try contents of a complete submission for the evaluation 
of proprietary names; 2010. [accessed 2014 June 03]. 
Available at: http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guid-
ances/ucm075068.pdf 
Justi FR, Pinheiro AMV. O efeito de vizinhança or-
tográfica no português do Brasil: acesso lexical ou 
processamento estratégico. Rev Interam Psicol 2006; 
40(3):275-288.
Aronson JK. Medication errors resulting from the 
confusion of drug names. Expert Opin Drug Saf 2004; 
3(3):167-172.
Lambert BL, Lin SJ, Tan H. Designing safe drug names. 
Drug Saf 2005; 28(6):495-512.
Lambert BL, Lin SJ, Chang KY, Gandhi SK. Similarity 
to the risk factor in drug-name Confusion errors: the 
look-alikes (orthographic) and sound-alikes (“phonet-
ic”), model. Med Care 1999; 37(12):1214-1225.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
2583
C
iên
cia &
 Saú
de C
oletiva, 20(8):2569-2583, 2015
American Medical Association. Rules for coining names; 
2014. [accessed 2014 July 17]. Available at: http://www.
ama-assn.org/ama/pub/physician-resources/medi-
cal-science/united-states-adopted-names-council/
naming-guidelines.page? 
Infarmed. Vademecum. [Handbook]; 2005. [accessed 
2014 June 03]. Available at: http://www.infarmed.pt/
portal/page/portal/INFARMED/PUBLICACOES/
TEMATICOS/VADEMECUM/vademecum.pdf 
World Health Organization. Guidelines on the Use of 
International Nonproprietary Names for Pharmaceutical 
Substances; 1997. [accessed 2014 July 11]. Available at: 
http://apps.who.int/medicinedocs/en/d/Jh1806e/ 
Mateus MH, Brito AM, Duarte I, Faria IH, Frota S, 
Matos G, Oliveira F, Vigário M, Villalva. Gramática da 
Língua Portuguesa. Lisboa, Portugal: Caminho; 2004.
Martins F, Vigário M, Frota S. FreP: Frequency Patterns 
of phonological objects in Portuguese (version 2.0) 
[Software].
Eurostat. Level of the foreign language reported as 
best-known in the country (self-reported) by sex. [ac-
cessed 2014 June 15]. Available at: http://appsso.eu-
rostat.ec.europa.eu/nui/show.do?dataset=edat_aes_
l51&lang=en 
Trancoso I, Ribeiro MC. On the pronunciation mode 
of acronyms in several european languages. In: George 
K, Nikos F, Evangelos D, Fifth European Conference 
on Speech Technology; 1997. [accessed 2014 July 11]. 
Available at: http://www.informatik.uni-trier.de/~ley/
db/conf/interspeech/eurospeech1997.html 
European Parliament. Directive 2004 /27/EC amending 
Directive 2001/83/EC on the Community code relating to 
medicinal products for human use; 2004. [accessed 2014 
June 15]. Available at: http://ec.europa.eu/health/files/
eudralex/vol-1/dir_2004_27/dir_2004_27_en.pdf
Nobre PF. Off-label prescriptions in Brazil and in the 
US: legal aspects and paradoxes. Cien Saude Colet 2014; 
18(3):847-854.
European Medicines Agency. Guideline on the readabil-
ity of the labelling and package leaflet; 2009. [accessed 
2014 June 15]. Available at: http://ec.europa.eu/health/
files/eudralex/vol-2/c/2009_01_12_readability_guide-
line_final_en.pdf 
Medilexicon. Medical Abbreviations Dictionary; 2014. 
[accessed 2014 July 11]. Available at: http://www.me-
dilexicon.com/medicalabbreviations.php 
Infarmed. Infomed: public data base containing infor-
mations about the Portuguese medicines; 2014. [accessed 
2014 July 11]. Available at: http://www.infarmed.pt/
infomed/inicio.php 
Nespor M, Vogel I. Prosodic Phonology. Dordrecht: 
Mouton de Gruyter; 1986.
Viana FL, Ribeiro IS, Maia J, Santos S. Propriedades 
psicométricas da prova de reconhecimento de palavras. 
Psicol. Reflex. Crit. 2013; 26(2):231-240.
Kenagy JW, Stein GC. Naming, labelling, and packag-
ing of pharmaceuticals. Am J Health Syst Pharm 2001; 
58(21):2033-2041.
Yap MJ, Balota DA, Sibley DE, Ratcliff R. Individual 
differences in visual word recognition: insights from 
the English Lexicon Project. J Exp Psychol Hum Percept 
Perform 2012; 38(1):53-79.
Marian V, Bartolotti J, Chabal S, Shook A. CLEAR-
POND: cross-linguistic easy-access resource for pho-
nological and orthographic neighborhood densities. 
PLoS One 2012; 7(8):e43230.
Food and Drug Administration. Consumers filling U.S. 
prescriptions abroad may get the wrong active ingredi-
ent because of confusing drug names; 2006. [accessed 
2014 June 03]. Available at: http://www.fda.gov/Drugs/
DrugSafety/PostmarketDrugSafetyInformationforPa-
tientsandProviders/ucm173134.htm
Cavaco A, Pires C, Vigário M. Medicine package inserts 
abbreviations and acronyms in Portuguese: exploring 
how difficult they are for educated people, in Medical 
Encounter. American Academy on Communication in 
Healthcare 2014; 27(2). 
Rohrmeier M, Fu Q, Dienes Z. Implicit learning of re-
cursive context-free grammars. PLoS One 2012; 7(10): 
e45885.
Bruning MC, Mosegui GB, Vianna CM. The use of 
phytotherapy and medicinal plants in primary health-
care units in the cities of Cascavel and Foz do Iguaçu 
- Paraná: the viewpoint of health professionals. Cien 
Saude Colet 2012; 17(10):2675-2685.
Blatt CR, Trauthman SC, Schmidt EH, Marchesan S, 
da Silva LM, Martins JL. General awareness and use of 
generic medication among citizens of Tubarão, state of 
Santa Catarina, Brazil. Cien Saude Colet 2012; 17(1):79-
87.
World’s Observatory. The 100 most spoken languages 
on the world; 2009. [accessed 2014 Jul 11]. Available 
at: http://frankherles.wordpress.com/2009/06/28/the-
100-most-spoken-languages-on-the-world/ 
Artigo apresentado em 14/09/2014
Aprovado em 27/11/2014
Versão final apresentada 29/11/2014
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
